
R&D Investor Event 2023
November 28, 2023 | London, UK
Watch the webcast
14:30 CET | 13:30 GMT | 08:30 EST

Investors Event Calendar
View recent presentations and learn more about upcoming events.

Third quarter results 2023
October 24, 2023 | Basel, Switzerland
Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.5 MB)
Interim financial report (PDF 0.6 MB)
Download the podcast (MP3 33 MB)
Download the interactive presentation (PDF 3.5 MB)
Novartis Q3 2023 Impact and Sustainability Update (PDF 1.0 MB)

Environmental, Social and Governance (ESG)
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.
ESG Updates: November 2023 (PDF 1.0 MB) | August 2023 (PDF 0.3 MB) | May 2023 (PDF 1.9 MB) | February 2023 (PDF 0.9 MB)
Latest updates: Impact & Health Equity (PDF 9.9 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.

Novartis Annual Reporting Suite
Read and download our integrated report, annual regulatory filings, and other disclosures.
Media Releases
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland